on SANOFI-AVENTIS (EPA:SAN)
Sanofi receives FDA approval for Infilbray, a new treatment for type 3 Gaucher disease
Sanofi announced that the FDA has approved Infilbray (venglustat), an oral treatment for type 3 Gaucher disease. This drug targets the debilitating neurological manifestations of this rare disease. The decision follows positive results from the Phase 3 LEAP2MONO trial, which demonstrated the efficacy of Infilbray compared to enzyme replacement therapy.
Infilbray crosses the blood-brain barrier and demonstrates significant improvements in neurological endpoints such as those measured by the Modified Ataxia Rating and Assessment Scale (SARA) and the Reproducible Neuropsychological Assessment Battery (RBANS) index. Sanofi plans to submit further global regulatory applications for Infilbray in 2026 and 2027.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SANOFI-AVENTIS news